Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.47 |
| ▸ | HTR7 | P34969 | 11/20 | 0.47 |
| ▸ | DRD2 | P14416 | 10/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4517586 | 0.99 | HTR1A (0.47) | HTR1AHTR7DRD2HSP90AB1DRD1 | |
| SCHEMBL4528441 | 0.86 | ADRA1D (0.53) | HTR1AHTR7DRD2HTR6ADRA1B | |
| Hydrochloric Acid SCHEMBL4534062 | 0.85 | ADRA1D (0.52) | HTR1AHTR7DRD2HTR6ADRA1B | |
| SCHEMBL4516386 | 0.83 | ADRA1B (0.50) | HTR1AHTR7DRD2DRD3ADRA1B | |
| SCHEMBL4522919 | 0.83 | HTR1A (0.42) | HTR1AHTR7DRD2DRD1DRD3 | |
| Hydrochloric Acid SCHEMBL4524800 | 0.82 | ADRA1B (0.49) | HTR1AHTR7DRD2DRD3ADRA1B | |
| SCHEMBL5592209 | 0.82 | HTR1A (0.51) | HTR1AHTR7DRD2DRD3HTR6 | |
| Hydrochloric Acid SCHEMBL4525100 | 0.82 | HTR1A (0.43) | HTR1AHTR7DRD2DRD1DRD3 | |
| Hydrochloric Acid SCHEMBL5592289 | 0.82 | ADRA1B (0.50) | HTR1AHTR7DRD2DRD3HTR6 | |
| SCHEMBL5598889 | 0.80 | HTR1A (0.44) | HTR1AHTR7DRD2HSP90AB1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-17 | — | — | US | claimed |
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-17 | — | — | US | disclosed |
| EP-1758583-A2 | ARYLPIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005118537-A2 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | ADRA1D, ADRB1, ADRA1A | HTR1A 16/4885HTR7 125/4885DRD2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.